Nomenclature
Short Name:
NEK10
Full Name:
Serine-threonine-protein kinase Nek10
Alias:
- NIMA (Never in mitosis gene a)-related kinase 10, isoform 1
- Hypothetical protein FLJ41066 (partial protein)
Classification
Type:
Protein-serine/threonine kinase
Group:
Other
Family:
NEK
SubFamily:
NA
Structure
Mol. Mass (Da):
133,229
# Amino Acids:
1172
# mRNA Isoforms:
7
mRNA Isoforms:
133,259 Da (1172 AA; Q6ZWH5); 82,881 Da (725 AA; Q6ZWH5-2); 81,624 Da (712 AA; Q6ZWH5-4); 54,221 Da (484 AA; Q6ZWH5-5); 53,075 Da (474 AA; Q6ZWH5-6); 47,765 Da (427 AA; Q6ZWH5-7); 25,494 Da (218 AA; Q6ZWH5-3)
4D Structure:
NA
1D Structure:
Subfamily Alignment
Domain Distribution:
| Start | End | Domain |
|---|---|---|
| 209 | 251 | Arm |
| 481 | 514 | Coiled-coil |
| 519 | 783 | Pkinase |
Post-translation Modifications
For detailed information on phosphorylation of this kinase go to PhosphoNET
Serine phosphorylated:
S98.
Threonine phosphorylated:
T189.
Tyrosine phosphorylated:
Y583, Y590, Y591.
Ubiquitinated:
K42.
Distribution
Based on gene microarray analysis from the NCBI
Human Tissue Distribution
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
38
1484
6
1221
45
1737
3
2071
-
-
-
-
5
189
29
590
24
924
9
512
0.2
6
9
5
0.2
8
10
5
22
843
6
1264
-
-
-
-
7
279
30
984
11
421
6
756
21
820
12
573
32
1242
2
391
100
3886
2
2190
28
1103
6
2003
7
277
7
470
1
37
144
135
58
2264
2
225
12
469
20
1387
16
607
30
975
18
697
6
1065
0.4
17
4
18
-
-
-
-
82
3174
4
894
8
317
6
449
18
688
18
469
37
1436
2
96
68
2649
2
1625
35
1359
2
356
3
107
14
68
-
-
-
-
4
149
7
89
0.05
2
12
0
18
698
26
605
6
229
22
202
Evolution
Species Conservation
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
100
100
100
84.8
85.1
99
83.4
84.6
-
-
-
-
-
-
-
81.6
83.6
-
-
-
-
84.8
89.2
94
-
-
-
-
-
-
42
46.3
-
-
-
70
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
29.2
49.2
30
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
For a wider analysis go to PhosphoNET Evolution in PhosphoNET
Regulation
Activation:
NA
Inhibition:
NA
Synthesis:
NA
Degradation:
NA
Protein Kinase Specificity
Matrix of observed frequency (%) of amino acids in aligned protein substrate phosphosites
Matrix Type:
Predicted from the application of the Kinexus Kinase Substrate Predictor Version 2.0 algorithm, which was trained with over 10,000 kinase-protein substrate pairs and 8,000 kinase-peptide substrate pairs.
Domain #:
1
Disease Linkage
General Disease Association:
Cancer
Specific Cancer Types:
Breast cancer
Comments:
Mutations are associated with susceptibility to breast cancer with tumour subtypes in BRCA1 and BRCA2 mutations carriers.
Mutagenesis Experiments:
Insertional mutagenesis studies in mice have not yet revealed a role for this protein kinase in mouse cancer oncogenesis.
Mutation Rate in All Cancers:
Percent mutation rates per 100 amino acids length in human cancers: 0.04 % in 24433 diverse cancer specimens. This rate is -52 % lower than the average rate of 0.075 % calculated for human protein kinases in general. Such a low frequency of mutation in human cancers is consistent with this protein kinase playing a role as a tumour requiring protein (TRP).
Mutation Rate in Specific Cancers:
Highest percent mutation rates per 100 amino acids length in human cancers: 0.33 % in 589 stomach cancers tested; 0.3 % in 864 skin cancers tested; 0.24 % in 603 endometrium cancers tested; 0.22 % in 1259 large intestine cancers tested; 0.16 % in 1634 lung cancers tested; 0.1 % in 710 oesophagus cancers tested; 0.1 % in 1512 liver cancers tested; 0.09 % in 548 urinary tract cancers tested; 0.09 % in 273 cervix cancers tested; 0.08 % in 833 ovary cancers tested; 0.05 % in 1316 breast cancers tested; 0.05 % in 1276 kidney cancers tested; 0.04 % in 238 bone cancers tested; 0.04 % in 1437 pancreas cancers tested; 0.03 % in 558 thyroid cancers tested; 0.03 % in 2009 haematopoietic and lymphoid cancers tested; 0.01 % in 942 upper aerodigestive tract cancers tested; 0.01 % in 881 prostate cancers tested; 0.01 % in 2103 central nervous system cancers tested.
Frequency of Mutated Sites:
Most frequent mutations with the number of reports indicated in brackets: P611L (5).
Comments:
Only 2 deletions, and no insertions or complex mutations are noted on the COSMIC website.